

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-11 (cancelled).

12. (currently amended): A substantially purified polypeptide comprising ~~amino acids 21-66 of SEQ ID NO:2 or SEQ ID NO:12~~ an amino acid sequence at least 85% identical to SEQ ID NO:4, provided said polypeptide comprises amino acids 67-98 of SEQ ID NO:4,
and wherein said polypeptide binds IL-10 or IL-22.

13. (currently amended): The polypeptide of claim 12, wherein said polypeptide comprises the amino acid sequence of ~~SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.~~

14. (original): A fusion polypeptide comprising the polypeptide of claim 12 operably linked to a non-CRF2-12 polypeptide.

15. (original): The fusion polypeptide of claim 14, wherein said non-CRF2-12 polypeptide comprises at least one member selected from the group consisting of an Fc region of an immunoglobulin molecules or a FLAG epitope, a HIS tag, and a MYC tag.

16. (original): A pharmaceutical composition comprising the polypeptide of claim 12 and a pharmaceutically acceptable carrier.

Claim 17 (cancelled).

18. (currently amended): A kit comprising in one or more containers ~~a compound selected from the group consisting of an CRF2-12 nucleic acid, an a.CRF2-12 polypeptide and an antibody to an CRF2-12 polypeptide.~~

Claims 9-64 (cancelled).

65. (new): The polypeptide of claim 12, wherein said polypeptide comprises one or more of the polypeptide sequences selected from the group consisting of

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),
FQSRNFHNILH/QWQ A/PG (SEQ ID NO:14),
SI/VYFVQYKM/TYGQS/RQW (SEQ ID NO:15),
TPRFTPWWETKL/IDPPV (SEQ ID NO:16),
LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),
RAVEIEG/ALI/TPHSSYCVVAEM/IYQPM (SEQ ID NO:18), and
DRRSP/QRSK/EERC VQ/EIP (SEQ ID NO:19).

66. (new): The polypeptide of claim 12, wherein said polypeptide comprises two or more of the polypeptide sequences selected from the group consisting of

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),
FQSRNFHNILH/QWQ A/PG (SEQ ID NO:14),
SI/VYFVQYKM/TYGQS/RQW (SEQ ID NO:15),

TPRFTPWWETKL/IDPPV (SEQ ID NO:16),
LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),
RAVEIEG/ALI/TPHSSYCVVAEM/TYQPM (SEQ ID NO:18), and
DRRSP/QRSK/EERCVCQ/EIP (SEQ ID NO:19).

67. (new): The polypeptide of claim 12, wherein said polypeptide comprises three or more of the polypeptide sequences selected from the group consisting of

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),
FQSRNFHNLH/QWQ A/PG (SEQ ID NO:14),
SI/VYFVQYKM/TYGQS/RQW (SEQ ID NO:15),
TPRFTPWWETKL/IDPPV (SEQ ID NO:16),
LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),
RAVEIEG/ALI/TPHSSYCVVAEM/TYQPM (SEQ ID NO:18), and
DRRSP/QRSK/EERCVCQ/EIP (SEQ ID NO:19).

68. (new): The polypeptide of claim 12, wherein said polypeptide comprises four or more of the polypeptide sequences selected from the group consisting of

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),
FQSRNFHNLH/QWQ A/PG (SEQ ID NO:14),
SI/VYFVQYKM/TYGQS/RQW (SEQ ID NO:15),
TPRFTPWWETKL/IDPPV (SEQ ID NO:16),
LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),
RAVEIEG/ALI/TPHSSYCVVAEM/TYQPM (SEQ ID NO:18), and

DRRSP/QRSK/EERCVQ/EIP (SEQ ID NO:19).

69. (new): The polypeptide of claim 12, wherein said polypeptide comprises five or more of the polypeptide sequences selected from the group consisting of

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),
FQSRNFHNLH/QWQ A/PG (SEQ ID NO:14),
SI/VYFVQYKM/IYGQS/RQW (SEQ ID NO:15),
TPRFTPWWETKL/IDPPV (SEQ ID NO:16),
LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),
RAVEIEG/ALI/TPHSSYCVVAEM/IYQPM (SEQ ID NO:18), and
DRRSP/QRSK/EERCVQ/EIP (SEQ ID NO:19).

70. (new): The polypeptide of claim 12, wherein said polypeptide comprises six or more of the polypeptide sequences selected from the group consisting of

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),
FQSRNFHNLH/QWQ A/PG (SEQ ID NO:14),
SI/VYFVQYKM/IYGQS/RQW (SEQ ID NO:15),
TPRFTPWWETKL/IDPPV (SEQ ID NO:16),
LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),
RAVEIEG/ALI/TPHSSYCVVAEM/IYQPM (SEQ ID NO:18), and
DRRSP/QRSK/EERCVQ/EIP (SEQ ID NO:19).

71. (new): The polypeptide of claim 12, wherein said polypeptide comprises the polypeptide sequences

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),
FQSRNFHNILH/QWQ A/PG (SEQ ID NO:14),
SI/VYFVQYKM/IYGQS/RQW (SEQ ID NO:15),
TPRFTPWWETKL/IDPPV (SEQ ID NO:16),
LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),
RAVEIEG/ALI/TPHSSYCVVAEM/TYQPM (SEQ ID NO:18), and
DRRSP/QRSK/EERCVQ/EIP (SEQ ID NO:19).

72. (new): The polypeptide of claim 12, wherein the amino acid sequence of said polypeptide is at least 90% identical to SEQ ID NO:4.

73. (new): The polypeptide of claim 12, wherein the amino acid sequence of said polypeptide is at least 95% identical to SEQ ID NO:4.

74. (new): The polypeptide of claim 12, wherein the amino acid sequence of said polypeptide is at least 98% identical to SEQ ID NO:4.

75. (new): The polypeptide of claim 12, wherein the amino acid sequence of said polypeptide is at least 99% identical to SEQ ID NO:4.

76. (new): The polypeptide of claim 12, wherein said polypeptide binds IL-10.

77. (new): The polypeptide of claim 12, wherein said polypeptide binds IL-22.

78. (new): A substantially purified polypeptide encoded by a polynucleotide that hybridizes at high stringency to the complement of SEQ ID NO:3, provided said polypeptide comprises amino acids 67-98 of SEQ ID NO:4, wherein said polypeptide binds IL-10 or IL-22.

79. (new): The polypeptide of claim 78, wherein said polypeptide binds IL-10.

80. (new): The polypeptide of claim 78, wherein said polypeptide binds IL-22.

81. (new): The polypeptide of claim 78, wherein said polypeptide comprises one or more of the polypeptide sequences selected from the group consisting of

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),

FQSRNFHNILH/QWQ A/PG (SEQ ID NO:14),

SI/VYFVQYKM/TYGQS/RQW (SEQ ID NO:15),

TPRFTPWWETKL/IDPPV (SEQ ID NO:16),

LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),

RAVEIEG/ALI/TPHSSYCVVAEM/IYQPM (SEQ ID NO:18), and

DRRSP/QRSK/EERCVQ/EIP (SEQ ID NO:19).

82. (new): The polypeptide of claim 78, wherein said polypeptide comprises two or more of the polypeptide sequences selected from the group consisting of

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),

FQSRNFHNILH/QWQ A/PG (SEQ ID NO:14),

SI/VYFVQYKM/TYGQS/RQW (SEQ ID NO:15),

TPRFTPWWETKL/IDPPV (SEQ ID NO:16),
LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),
RAVEIEG/ALI/TPHSSYCVVAEM/IYQPM (SEQ ID NO:18), and
DRRSP/QRSK/EERCVQ/EIP (SEQ ID NO:19).

83. (new): The polypeptide of claim 78, wherein said polypeptide comprises three or more of the polypeptide sequences selected from the group consisting of

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),
FQSRNFHNILH/QWQ A/PG (SEQ ID NO:14),
SI/VYFVQYKM/IYGQS/RQW (SEQ ID NO:15),
TPRFTPWWETKL/IDPPV (SEQ ID NO:16),
LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),
RAVEIEG/ALI/TPHSSYCVVAEM/IYQPM (SEQ ID NO:18), and
DRRSP/QRSK/EERCVQ/EIP (SEQ ID NO:19).

84. (new): The polypeptide of claim 78, wherein said polypeptide comprises four or more of the polypeptide sequences selected from the group consisting of

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),
FQSRNFHNILH/QWQ A/PG (SEQ ID NO:14),
SI/VYFVQYKM/IYGQS/RQW (SEQ ID NO:15),
TPRFTPWWETKL/IDPPV (SEQ ID NO:16),
LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),
RAVEIEG/ALI/TPHSSYCVVAEM/IYQPM (SEQ ID NO:18), and

DRRSP/QRSK/EERCVQ/EIP (SEQ ID NO:19).

85. (new): The polypeptide of claim 78, wherein said polypeptide comprises five or more of the polypeptide sequences selected from the group consisting of

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),

FQSRNFHNILH/QWQ A/PG (SEQ ID NO:14),

SI/VYFVQYKM/IYGQS/RQW (SEQ ID NO:15),

TPRFTPWWETKL/IDPPV (SEQ ID NO:16),

LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),

RAVEIEG/ALI/TPHSSYCVVAEM/IYQPM (SEQ ID NO:18), and

DRRSP/QRSK/EERCVQ/EIP (SEQ ID NO:19).

86. (new): The polypeptide of claim 78, wherein said polypeptide comprises six or more of the polypeptide sequences selected from the group consisting of

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),

FQSRNFHNILH/QWQ A/PG (SEQ ID NO:14),

SI/VYFVQYKM/IYGQS/RQW (SEQ ID NO:15),

TPRFTPWWETKL/IDPPV (SEQ ID NO:16),

LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),

RAVEIEG/ALI/TPHSSYCVVAEM/IYQPM (SEQ ID NO:18), and

DRRSP/QRSK/EERCVQ/EIP (SEQ ID NO:19).

87. (new): The polypeptide of claim 78, wherein said polypeptide comprises the polypeptide sequences

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),
FQSRNFHNILH/QWQ A/PG (SEQ ID NO:14),
SI/VYFVQYKM/IYGQS/RQW (SEQ ID NO:15),
TPRFTPWWETKL/IDPPV (SEQ ID NO:16),
LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),
RAVEIEG/ALI/TPHSSYCVVAEM/IYQPM (SEQ ID NO:18), and
DRRSP/QRSK/EERCVCQ/EIP (SEQ ID NO:19).

88. (new): A fusion polypeptide comprising the polypeptide of claim 78 operably linked to a non-CRF2-12 polypeptide.

89. (new): The fusion polypeptide of claim 88, wherein said non-CRF2-12 polypeptide comprises at least one member selected from the group consisting of an Fc region of an immunoglobulin molecule, a FLAG epitope, a HIS tag, and a MYC tag.

90. (new): The fusion polypeptide of claim 88, wherein said non-CRF2-12 polypeptide comprises an Fc region of an immunoglobulin molecule.

91. (new): A pharmaceutical composition comprising the polypeptide of claim 78 and a pharmaceutically acceptable carrier.